BioCentury
ARTICLE | Clinical News

FDA approves GW’s Epidiolex, first marijuana-derived drug

June 29, 2018 2:55 PM UTC

FDA approved Epidiolex cannabidiol from GW Pharmaceuticals plc (NASDAQ:GWPH) on June 25, marking the first U.S. approval of a marijuana-derived purified substance, according to the agency. Epidiolex is indicated to treat seizures associated with Lennox-Gastaut syndrome and Dravet syndrome -- two rare forms of epilepsy -- in patients ages two and older. FDA said it is also the first drug approved for Dravet syndrome.

Epidiolex is an oral liquid formulation of cannabidiol (CBD), a phytocannabinoid found in Cannabis sativa. The company told BioCentury it has not yet determined a price...

BCIQ Company Profiles

GW Pharmaceuticals plc